Furthermore, these results suggest similar analyses of KIR/KIR-ligand genotype and immunotherapy should be pursued for other clinical trials in other diseases that utilize other tumor-reactive mAbs to see if these findings we have noted for rituximab in FL and dinutuximab in neuroblastoma might extend to other cancers treated with other tumor-reactive mAb [40]. Here, KIR3DL1 is linked to neoplasm.